Alexion Pharmaceuticals has made an all-cash offer to acquire Wilson Therapeutics for a total of SEK7.1 B (US$852 M). Alexion currently relies on its successful rare disease treatment Soliris® (eculizumab) to generate the majority of its revenue, however with competition looming it needs to expand its pipeline. Wilson’s lead candidate is WTX101, a potential first-in-class Phase III candidate to treat Wilson’s disease, a rare liver disorder of impaired copper transport.